CIK 0001541157 · Non-accelerated filer<br>Smaller reporting company
Akari Therapeutics Plc
Sign in to watch- Ticker
- AKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- EIN
- 981034922
- Phone
- (929) 274-7510
- Business address
- 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FL, 33602
- Former names
- Celsus Therapeutics Plc., Morria Biopharmaceuticals PLC
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- S-8 Other Securities Offered to Employees in Benefit Plans
- 8-K Event Shareholder vote results
- 4 Grant or award Director acquired 12,312 shares (grant or award)
- 4 Grant or award Director acquired 23,409 shares (grant or award)
- 4 Grant or award Director acquired 16,413 shares (grant or award)
- 4 Grant or award Director acquired 17,777 shares (grant or award)
- 4 Option exercise CEO acquired 27,066 shares (option exercise)
- 4 Grant or award Director acquired 8,536 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- DEF 14A Proxy Proxy Statement
- 4 Grant or award CEO acquired 6,430 shares (grant or award)
- 8-K Event Executive or director change
- 4 Grant or award Interim CFO acquired 1,728 shares (grant or award)
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Grant or award Interim CFO acquired 1,130 shares (grant or award)
Page 1 of 38 · 744 filings